Doctors are increasingly turning to monoclonal-antibody drugs to treat high-risk patients who get sick with Covid-19. WSJ takes a look at how the therapies work and why they’re important for saving lives. Illustration: Jacob Reynolds/WSJ More from the Wall Street…
The COVID-19 pandemic has prompted scientists to use adaptive research designs to evaluate potential treatments simultaneously and efficiently, increasing the likelihood that patients will receive treatments most likely to be effective for them. Lennie Derde, MD of @UMC Utrecht and…
Auto-Antibodies are misguided antibodies that target proteins of the body, instead of viral proteins. When autoantibodies bind to self-proteins, they generate an immune response against them. This can disrupt their normal function, cause widespread inflammation & tissue damage, and lead…
Gene Dolgoff CEO Holobeam Technologies Inc Holobeam’s 28-member team includes world-class entrepreneurs, scientists, doctors, and engineers, including the inventor of holographic medical imaging technologies, hologram mass-production, and the LCD Projector; the inventor and developers of the MRI; and early developers…